MedTrace Logo

Obstructive Sleep Apnea Syndrome in Glaucoma

NCT00313092 · Status: TERMINATED · Type: OBSERVATIONAL · Enrollment: 60

Last updated 2015-10-02

No results posted yet for this study

Summary

The aim of the study is to determine if plasma matrix-metalloproteinase activity can predict glaucoma in patients with OSAS and if the level of plasma matrix-metalloproteinase activity will decrease after one month of nCPAP-treatment.

Conditions

  • Obstructive Sleep Apnea Syndrome
  • Glaucoma

Interventions

DEVICE

nCPAP treatment

treatment with positive air pressure during night

Sponsors & Collaborators

  • University Hospital, Basel, Switzerland

    collaborator OTHER

  • Selim Orguel

    lead OTHER

Principal Investigators

  • Selim Orgül, MD · University Eye Clinic Basel

Eligibility

Min Age
18 Years
Max Age
95 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2005-01-31
Primary Completion
2005-09-30
Completion
2005-09-30

Countries

  • Switzerland

Study Locations

More Related Trials

Entities

Diseases

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00313092 on ClinicalTrials.gov